SCHEMBL16029366

SCHEMBL16029366

CCCOCc1nc2c(c(=O)n(C)c(=O)n2C)n1Cc1ccc(F)cc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 5/20 0.61
SMN1; SMN2 Q16637 4/20 0.61
TP53 P04637 2/20 0.61
LMNA P02545 2/20 0.61
TSHR P16473 5/20 0.61
HSD17B10 Q99714 2/20 0.59
CASP1 P29466 1/20 0.59
CASP7 P55210 1/20 0.59
MAPK1 P28482 2/20 0.58
GFER P55789 1/20 0.58
USP2 O75604 1/20 0.56
ALOX15 P16050 1/20 0.56
MAPT P10636 4/20 0.55
PCSK9 Q8NBP7 1/20 0.55
KMT2A Q03164 1/20 0.55
MAOA P21397 2/20 0.54
MAOB P27338 2/20 0.54
ALDH1A1 P00352 2/20 0.53
NPSR1 Q6W5P4 1/20 0.52
NCOA3 Q9Y6Q9 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16079532 0.91 HTT (0.60) HTTSMN1; SMN2TP53LMNATSHR
SCHEMBL16029914 0.90 ALDH1A1 (0.60) HTTSMN1; SMN2TP53TSHRHSD17B10
SCHEMBL16028631 0.89 SMN1; SMN2 (0.52) HTTSMN1; SMN2TP53LMNATSHR
SCHEMBL16029663 0.88 ALDH1A1 (0.59) HTTSMN1; SMN2LMNATSHRHSD17B10
SCHEMBL16029316 0.88 HTT (0.63) HTTSMN1; SMN2TP53LMNATSHR
SCHEMBL16029603 0.88 MAOA (0.59) HTTSMN1; SMN2TP53LMNATSHR
SCHEMBL16029591 0.87 PCSK9 (0.48) HTTSMN1; SMN2TP53LMNATSHR
SCHEMBL16029923 0.87 HSD17B10 (0.50) HTTSMN1; SMN2TP53LMNATSHR
SCHEMBL16029557 0.87 SMN1; SMN2 (0.49) HTTSMN1; SMN2TP53LMNATSHR
SCHEMBL16029238 0.86 HSD17B10 (0.49) HTTSMN1; SMN2TP53LMNATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2970316-B1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES INC (US) 2017-11-08 EP disclosed
US-20160145257-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. 2016-05-26 US disclosed
US-20140275528-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF HYDRA BIOSCIENCES, INC. (US) 2014-09-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160145257-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 HTT 1025/4885SMN1; SMN2 1307/4885TP53 4229/4885
US-20140275528-A1 SUBSTITUTED XANTHINES AND METHODS OF USE THEREOF TRPC5, TRPC7, TRPC4 HTT 1025/4885SMN1; SMN2 1307/4885TP53 4229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.